<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095116</url>
  </required_header>
  <id_info>
    <org_study_id>SP-1011-004</org_study_id>
    <nct_id>NCT05095116</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol for Patients With Eosinophilic Esophagitis</brief_title>
  <official_title>APT-1011 (Fluticasone ODT) Expanded Access Protocol for Patients With Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ellodi Pharmaceuticals, LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ellodi Pharmaceuticals, LP</source>
  <brief_summary>
    <textblock>
      This expanded access program is an open-label, single-arm design where consenting patients&#xD;
      may participate up until APT-1011 is commercially available in the relevant regions or the&#xD;
      protocol is terminated by the Sponsor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive a 120-day supply of APT-1011 and will attend scheduled clinic visits&#xD;
      every 4 months. Telephone visits will be performed as needed. At each clinic visit (or&#xD;
      additional telephone visit), adverse events (AEs) and concomitant medications will be&#xD;
      collected. The Global EoE score will be collected at clinic visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Eosinophilic Esophagitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APT-1011 3 mg HS</intervention_name>
    <description>APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.</description>
    <other_name>fluticasone propionate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female â‰¥12 years of age at the time of informed consent&#xD;
&#xD;
          2. Signed ICF and willing and able to adhere to all procedures; signed assent form and&#xD;
             parent/guardian ICF must also be collected for adolescents&#xD;
&#xD;
          3. Confirmed medical history of EoE&#xD;
&#xD;
          4. Adult and adolescent patients who are unable or ineligible to enroll in an APT-1011&#xD;
             clinical study or have failed available treatment options&#xD;
&#xD;
          5. Willing and able to adhere to the treatment regimen and visit schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have known contraindication, hypersensitivity, or intolerance to corticosteroids&#xD;
&#xD;
          2. Have signs and symptoms of adrenal suppression or hypercorticism&#xD;
&#xD;
          3. Use of potent CYP3A4 inhibitors (e.g., ritonavir and ketoconazole) are prohibited&#xD;
&#xD;
          4. Have current alcohol or drug abuse in the opinion of the Investigator&#xD;
&#xD;
          5. Female patients who are pregnant, breastfeeding, or planning to become pregnant while&#xD;
             participating in the program&#xD;
&#xD;
          6. Female patients of child-bearing potential who are unable to comply with adequate&#xD;
             contraception use during the program&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Karol Knoop, RN, BS, CCTA</last_name>
    <phone>(609) 450-1312</phone>
    <email>karol.knoop@ellodipharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amir Karimzadeh, Pharm.D.</last_name>
    <phone>(503) 330-1337</phone>
    <email>amir.karimzadeh@ellodipharma.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>APT-1011</keyword>
  <keyword>Esophagitis</keyword>
  <keyword>Eosinophilic Esophagitis</keyword>
  <keyword>Esophageal Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Gastroenteritis</keyword>
  <keyword>Eosinophilia</keyword>
  <keyword>Leukocyte Disorders</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Hypersensitivity, Immediate</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Fluticasone</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Bronchodilator Agents</keyword>
  <keyword>Autonomic Agents</keyword>
  <keyword>Peripheral Nervous System Agents</keyword>
  <keyword>Anti-Asthmatic Agents</keyword>
  <keyword>Respiratory System Agents</keyword>
  <keyword>Anti-Allergic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

